Skip to main content
Clinical Trials/NCT01452165
NCT01452165
Completed
N/A

Observational Study on Cardiac Morphology and Function in Patients With Peripheral Artery Disease in Vastmanland County, Sweden(PADVa).

Uppsala University1 site in 1 country457 target enrollmentMay 2006

Overview

Phase
N/A
Intervention
Not specified
Conditions
Peripheral Vascular Diseases
Sponsor
Uppsala University
Enrollment
457
Locations
1
Primary Endpoint
Left ventricular ejection fraction (cross-sectional outcome measure)
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The main purposes of this study are:

  • to describe the prevalence and degree of reduced left ventricular function and hypertrophy in patients with peripheral arterial disease in comparison to controls from the general population,
  • to evaluate factors of importance to left ventricular dysfunction and hypertrophy in patients with peripheral arterial disease, and
  • to assess the impact of cardiac function and left ventricular hypertrophy on long-term prognosis in patients with peripheral artery disease.

Detailed Description

Left ventricular dysfunction is often a consequence of coronary heart disease (CHD). CHD is prevalent among patients with peripheral artery disease. However, there is limited data regarding left ventricular morphology and function in those patients. In the cross-sectional part of this study we will describe the prevalence of reduced cardiac function and left ventricular hypertrophy in a cohort of patients with peripheral artery disease. The patient outcomes will be compared to control subjects randomly selected from the general population in a case-control design. Further, clinical and genetic determinants of cardiac dysfunction in the patient cohort will be identified. In the longitudinal part of the study, the impact of cardiac function and morphology on cardiovascular mortality and morbidity will be evaluated in the cohort.

Registry
clinicaltrials.gov
Start Date
May 2006
End Date
May 2011
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Uppsala University
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Fulfillment of at least one of the following criteria:
  • ankle-brachial-index (ABI) \<= 0.9, or
  • stenosis of \> 30% of the internal carotid artery, or
  • symptoms typical for claudication and corresponding stenotic findings on the ultrasound examination.

Exclusion Criteria

  • age less than 18 years
  • severly impaired communication capabilities

Outcomes

Primary Outcomes

Left ventricular ejection fraction (cross-sectional outcome measure)

Time Frame: baseline

LVEF obtained by echocardiographic biplane disk summation method. In the cross-sectional study, the mean value of LVEF and the prevalence of reduced LVEF (LVEF \< 50%) in the patient group will be compared to the control group.

Cardiovascular events (longitudinal outcome measure)

Time Frame: 5-10 years

Cardiovascular events obtained from the Swedish National Causes of Death register and the Swedish National In-patient register. The registers are linked to the patients by the unique personal identification number assigned to each swedish resident.

Left ventricular mass (cross-sectional outcome measure)

Time Frame: baseline

Left ventricular mass obtained by 2-dimensional echocardiography according to the American Society of Echocardiography.

Secondary Outcomes

  • Wall motion score index (WMSI)(baseline)
  • Echocardiographic left ventricular filling variables(baseline)

Study Sites (1)

Loading locations...

Similar Trials